Literature DB >> 15902697

Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma.

Anders Malmsten1, Xing-Wu Shao, Staffan Sjödahl, Eva-Lena Fredriksson, Ingvar Pettersson, Thomas Leitner, Clas F R Källander, Eric Sandström, J Simon Gronowitz.   

Abstract

A more sensitive version of ExaVir Load, a test that utilizes reverse transcriptase (RT) activity from virions in plasma to determine HIV-1 viral load, is described. The virions were immobilized on a gel that was washed, followed by lysis of the virions, elution of purified RT, and finally RT activity determination. The changes made to the original test were: (1) improved washing of the immobilized virions by addition of a non-lytic detergent to the wash buffer, (2) improved virion lysis procedure, including changes in salt, detergent and pH, (3) the use of larger sample volumes in the RT assay, and (4) prolonged RT reaction time. The alterations gave a tenfold increased sensitivity compared to the original version. The correlation between RT load by the current test and RNA PCR was the same as previously (r=0.90). Using colorimetric product detection, the average detection limit in a panel of 262 patient plasma from Stockholm was 0.5 fg RT/ml, corresponding to approximately 170 RNA copies/ml. None of 54 HIV-1 RNA negative samples exhibited RT. The amount of RT load positive samples were 19% for samples containing 50-400 RNA, 71% for samples with 400-1,500, and 100% among samples with >8,000 copies/ml (according to Roche Amplicor). The sensitivity could be increased further using fluorimetric detection. In conclusion, the modifications of the test described result in an important increase in sensitivity. It can now be regarded as a competitive alternative method for HIV viral load determinations. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15902697     DOI: 10.1002/jmv.20360

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  16 in total

1.  Evaluation of the Cavidi ExaVir Load assay (version 3) for plasma human immunodeficiency virus type 1 load monitoring.

Authors:  Vicki L Greengrass; Megan M Plate; Pauline M Steele; Justin T Denholm; Catherine L Cherry; Lisa M Morris; Anna Hearps; Suzanne M Crowe
Journal:  J Clin Microbiol       Date:  2009-07-15       Impact factor: 5.948

2.  Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resource-limited settings.

Authors:  Sumathi Sivapalasingam; Shaffiq Essajee; Phillipe N Nyambi; Vincenza Itri; Bruce Hanna; Robert Holzman; Fred Valentine
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay.

Authors:  Cheryl Jennings; Susan A Fiscus; Suzanne M Crowe; Aleksandra D Danilovic; Ralph J Morack; Salvatore Scianna; Ada Cachafeiro; Donald J Brambilla; Jorg Schupbach; Wendy Stevens; Richard Respess; Oliviero E Varnier; Gary E Corrigan; J Simon Gronowitz; Michael A Ussery; James W Bremer
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

4.  Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay.

Authors:  Paul Stewart; Ada Cachafeiro; Sonia Napravnik; Joseph J Eron; Ian Frank; Charles van der Horst; Ronald J Bosch; Daniel Bettendorf; Peter Bohlin; Susan A Fiscus
Journal:  J Clin Virol       Date:  2010-09-15       Impact factor: 3.168

5.  Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients.

Authors:  Pedro Borrego; Maria Fátima Gonçalves; Perpétua Gomes; Lavínia Araújo; Inês Moranguinho; Inês Brito Figueiredo; Isabel Barahona; José Rocha; Claudino Mendonça; Maria Cesarina Cruz; Jorge Barreto; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2017-05-17       Impact factor: 5.948

6.  Assessment of the low-cost Cavidi ExaVir Load assay for monitoring HIV viral load in pediatric and adult patients.

Authors:  Vicki Greengrass; Barbera Lohman; Lisa Morris; Megan Plate; Pauline M Steele; Judd L Walson; Suzanne M Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2009-11-01       Impact factor: 3.731

7.  Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays.

Authors:  Lesley E Scott; Lara D Noble; Jackie Moloi; Linda Erasmus; Willem D F Venter; Wendy Stevens
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

8.  HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays.

Authors:  Sonia Napravnik; Ada Cachafeiro; Paul Stewart; Joseph J Eron; Susan A Fiscus
Journal:  J Clin Virol       Date:  2009-11-05       Impact factor: 3.168

9.  Comparative evaluation of the ExaVir Load version 3 reverse transcriptase assay for measurement of human immunodeficiency virus type 1 plasma load.

Authors:  Wendy Labbett; Ana Garcia-Diaz; Zoe Fox; Gillian S Clewley; Thomas Fernandez; Margaret Johnson; Anna Maria Geretti
Journal:  J Clin Microbiol       Date:  2009-08-05       Impact factor: 5.948

10.  A highly sensitive aptamer-based HIV reverse transcriptase detection assay.

Authors:  Jeffrey J DeStefano; Irani Alves Ferreira-Bravo
Journal:  J Virol Methods       Date:  2018-04-06       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.